Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide in Myelodysplastic Syndrome
NCT00044382Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Feb 2002
- Primary completion
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in myelodysplastic syndrome (MDS), sponsored by Celgene Corporation. Started Feb 2002; status: completed.
02
Drugs
lenalidomide
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00044382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00044382.